You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Retrovir is indicated for: . Treatment of adult patients with severe symptomatic human immunodeficiency virus infection (AIDS or advanced AIDS related complex); . Treatment of other HIV-positive adult patients with less than 500 CD4 cells/mm3. Notes: (1) The limited available data currently support the extended use of Retrovir (Indication 2 above). (2) The optimal dosage for these indications has not been established. . Combination therapy in advanced HIV infection. The addition of HIVID (zalcitabine) may be considered for the management of adult patients with advanced HIV infection and CD4 + cell counts less than or equal to 200/mm3, who have received Retrovir monotherapy for less than 12 months. Retrovir monotherapy is still indicated as initial therapy for adult patients with HIV infection who fulfil the approved indications. NEW INDICATIONS APPROVED 7TH FEBRUARY 1997: Retrovir (zidovudine) is indicated for the treatment of HIV infection, alone and in combination with other antiretroviral therapies. The optimum dosage for this indication has not been established.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Retrovir is indicated for: . Treatment of adult patients with severe symptomatic human immunodeficiency virus infection (AIDS or advanced AIDS related complex); . Treatment of other HIV-positive adult patients with less than 500 CD4 cells/mm3. Notes: (1) The limited available data currently support the extended use of Retrovir (Indication 2 above). (2) The optimal dosage for these indications has not been established. . Combination therapy in advanced HIV infection. The addition of HIVID (zalcitabine) may be considered for the management of adult patients with advanced HIV infection and CD4 + cell counts less than or equal to 200/mm3, who have received Retrovir monotherapy for less than 12 months. Retrovir monotherapy is still indicated as initial therapy for adult patients with HIV infection who fulfil the approved indications. NEW INDICATIONS APPROVED 7TH FEBRUARY 1997: Retrovir (zidovudine) is indicated for the treatment of HIV infection, alone and in combination with other antiretroviral therapies. The optimum dosage for this indication has not been established.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on January, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
(1) Treatment of adult patients with severe symptomatic human immunodeficiency virus infection (AIDS or advanced AIDS related complex). (2) Treatment of other HIV-positive adult patients with less than 500 CD4 cells/mm3. New indications as at 11 May 1994: Retrovir is indicated for: . Treatment of adult patients with severe symptomatic human immunodeficiency virus infection (AIDS or advanced AIDS related complex); . Treatment of other HIV-positive adult patients with less than 500 CD4 cells/mm3. Notes: (1) The limited available data currently support the extended use of Retrovir (indication 2 above). (2) The optimal dosage for these indications has not been established . Combination therapy in advanced HIV infection: The addition of HIVID (zalcitabine) may be considered for the management of adult patients with advanced HIV infection and CD4 + cell counts less than or equal to 200/mm3, who have received Retrovir monotherapy for less than 12 months. Retrovir monotherapy is still indicated as initial therapy for adult patients with HIV infection who fulfil the approved indications. NEW INDICATION APPROVED 7TH FEBRUARY 1997: Retrovir (zidovudine) is indicated for the treatment of HIV infection, alone and in combination with other antiretroviral therapies. The optimum dosage for this indication has not been established.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on January, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Retrovir is indicated for: . Treatment of adult patients with severe symptomatic human immunodeficiency virus infection (AIDS or advanced AIDS related complex); . Treatment of other HIV-positive adult patients with less than 500 CD4 cells/mm3. Notes: (1) The limited available data currently support the extended use of Retrovir (Indication 2 above). (2) The optimal dosage for these indications has not been established. . Combination therapy in advanced HIV infection. The addition of HIVID (Zalcitabine) may be considered for the management of adult patients with advanced HIV infection and CD4 + cell counts less than or equal to 200/mm3, who have received Retrovir monotherapy for less than 12 months. Retrovir monotherapy is still indicated as initial therapy for adult patients with HIV infection who fulfil the approved indications. NEW INDICATIONS APPROVED 7TH FEBRUARY 1997: Retrovir (zidovudine) is indicated for the treatment of HIV infection, alone and in combination with other antiretroviral therapies. The optimum dosage for this indication has not been established.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on January, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
